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Néstor Toapanta1,2, Irina B. Torres1,2, Joana Sellarés1,2, Betty Chamoun1,2,
Daniel Serón1,2 and Francesc Moreso1,2
1Department of Nephrology, Hospital Universitari Vall d’Hebron, Barcelona, Spain and 2Department of
Medicine, Autonomous University of Barcelona, Barcelona, Spain
Correspondence to: Francesc Moreso; E-mail: fjmoreso@vhebron.net
ABSTRACT
Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal
transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection,
complications and infection-related death. During this year a large amount of information from nationwide registries,
multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-
19 was higher than in the general population, but the lower threshold for testing may have contributed to its better
identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent
in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ
transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the
general population. Kidney transplant recipients experience a high mortality rate compared with the general population,
especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes
in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very
early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is
high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and
strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and
calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is caused by the single-
strand RNA virus called severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) and has become a worldwide threat.
The first human case of COVID-19 was reported in Wuhan,
China, in December 2019, and within a few weeks the infection
spread around the world, becoming a pandemic [1]. A total of
>62 million people have been diagnosed and 1.45 million died
(https://coronavirus.jhu.edu/map.html; accessed 28 November
2020). There was an initial wave during March and April 2020
until a lockdown was ordered by many national governments.
After progressive lifting of the lockdowns, a second wave is
evolving, with the USA, India, Brazil, Russia, France and Spain
having the highest rates of infection. Fever, fatigue and dry
cough are the most common symptoms and patients may also
experience shortness of breath, myalgia, sore throat and
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gastrointestinal (GI) symptoms [2]. Reverse transcription poly-
merase chain reaction (RT-PCR) is the gold standard for
diagnosis. Treatment is based on oxygen supply and a
combination of drugs that have evolved during the pandemic.
Initially drugs with potential antiviral activity (e.g. lopinavir/ri-
tonavir, hydroxychloroquine) were widely used, but later, ran-
domized prospective trials demonstrated their lack of efficacy
[3] and only remdesivir has been approved by regulatory agen-
cies to treat COVID-19 [4]. Now the agents being studied to miti-
gate the clinical impact of this infection and decrease its
severity are focused on immune mediators, stem cells and
agents intended specifically to improve or support lung function
(https://www.wcgclinical.com/covid-19/covid-19-trial-insights).
Renal transplant patients have been one of the populations
most vulnerable to COVID-19 and many reports have been pub-
lished. In this setting, immunomodulation has emerged as a
promising option for patients with COVID-19-related cytokine
storm, but the supporting evidence is scarce and of low quality
[5]. Moreover, COVID-19 has had a big impact on wait-listed
patients, highlighting the need to properly balance the risks and
benefits of transplantation in the setting of an ongoing
pandemic [6].
The aim of this article is to review the available literature
published until now regarding renal and patient prognosis in
renal transplant patients with COVID-19.
EPIDEMIOLOGY OF COVID-19 IN RENAL
TRANSPLANT PATIENTS ACROSS THE WORLD
Since the outbreak, a lot of information has been available from
nationwide registries and multicentre and local studies. A
European study conducted by the ERA-EDTA from the French
and Spanish registry yielded an average infection rate of 14/
1000 transplants at risk [7]. The Spanish registry [8], with a lon-
ger period of observation, showed an incidence of 17.7/1000
transplants, while the French registry [9], with a shorter obser-
vation period, showed an incidence of 9.5/1000 transplants. The
kidney registry of the Dutch-speaking Belgian Society of
Nephrology reports a similar incidence of 14.0/1000 transplants
[10]. Similar incidences were reported from multicentre studies
including patients from the USA, Italy and Spain [11, 12].
Importantly, the incidence during the observation periods was
2–5 times higher in renal transplants than in the general popu-
lation. Even in small countries like Scotland with a lower
COVID-19 incidence, with only 24 transplant patients diagnosed
with COVID-19, the incidence was 3 times that of the general
population [13]. However, single-centre analysis conducted in
areas with a high rate of infection revealed higher incidences
[14–16]. A summary of the larger studies conducted is shown in
Table 1. During the initial wave there were no studies providing
information about asymptomatic patients since they were not
generally screened. During the first wave, the hospitalization
rate of symptomatic patients with COVID-19 was >80% in the
nationwide registries and multicentre studies (Table 1).
Likewise, in a cohort of 44 patients with mild symptoms, 34
needed to be referred to the emergency department and man-
aged as inpatients while only 9 patients with suspected COVID-
19 (never tested due to limitations) were managed as outpa-
tients, and the only patient with confirmed COVID-19 was never
hospitalized [17]. Finally, in a cohort of 41 patients, the hospital-
ization rate was 55% for those patients with confirmed COVID-
19 while it was 5% for suspected but never tested patients [18].
Tests to detect antibodies against SARS-CoV-2 were incorpo-
rated into clinical practice later and they allow characterizing
the proportion of asymptomatic or pauci-symptomatic patients
not screened by RT-PCR. In a large study conducted in the Bronx
borough of New York City, the combination of RT-PCR and anti-
bodies characterized an incidence as high as 234/1000 trans-
plant patients, with 41% diagnosed only by the presence of
antibodies against SARS-CoV-2 [19]. For symptomatic patients
(PCR positive), the hospitalization rate was high (84.1%), while
for the overall cohort it was lower (48.5%).
Thus, although the number of renal transplant patients di-
agnosed with COVID-19 was higher than in the general popula-
tion, the lower threshold for testing may have contributed to its
better identification while many oligosymptomatic individuals
in the general population were not tested and do not appear in
the official statistics [10].
The mean age of renal transplant patients with COVID-19
was 60 years and the proportion of males (two-thirds) and
comorbidities (arterial hypertension >80%, diabetes >25%) cor-
relates with the characteristics of transplanted patients.
Clinical presentation is characterized by fever, cough and short-
ness of breath in >60% of patients, while GI symptoms were de-
scribed in about one-third of patients [20].
AKI IN RENAL TRANSPLANT PATIENTS WITH
COVID-19
Acute kidney injury (AKI) is a common complication in patients
with COVID-19 and is associated with increased intensive care
unit (ICU) admission and mortality [21, 22]. AKI incidence is
higher in patients admitted to the ICU due to COVID-19 than in
patients admitted for other reasons [23]. In a large retrospective
study (9657 patients), 39.9% developed AKI, of which 6.6% re-
quired renal replacement therapy (RRT) [24]. Approximately
one-third of patients with AKI do not fully recover renal func-
tion [25]. The main risk factors associated with AKI are ad-
vanced age, male gender, severity of respiratory impairment,
mechanical ventilation, pre-existing chronic renal failure, co-
infection with other organisms and systemic inflammatory re-
sponse [22–24]. Noticeably, AKI was increased in the subgroups
with diabetes compared with subgroups without this condition
[26]. A group to highlight is patients of African descent, in
whom a greater risk of COVID-19 infection has been described
[22, 27, 28]. In this population, the APOL1 genotype is closely re-
lated to the development of nephropathy and evidence suggests
that the SARS-CoV-2 infection could act as a ‘second blow’ that
leads to podocyte dysregulation [29].
Considering that kidney transplant patients have a single
functional kidney, receive a tacrolimus-based regimen that has
nephrotoxic effects [30], have a high prevalence of hypertension
and diabetes [31] and that Black race increases the risk of AKI in
kidney recipients [32, 33], a higher incidence and severity of AKI
in these settings would be expected. However, few studies have
attempted to compare AKI in kidney transplant patients with
the general population. Aziz et al. [34] reviewed 19 articles
reporting AKI incidence in kidney transplant and non-
transplanted patients. Despite the fact that AKI incidence was
higher in kidney transplant patients (27.5% versus 13.3%), as
well as RRT (15.4% versus 3.3%), the mortality rate was similar
between groups. In a systemic review conducted by Marinaki et
al. [35] including 420 patients, 44% of hospitalized kidney trans-
plant patients developed AKI and 23% required RRT. In a multi-
centre study including 104 hospitalized kidney transplant
i22 | N. Toapanta et al.
patients, AKI was observed in 47% of patients and, interestingly,
it was observed that tacrolimus trough levels were higher in
patients with Stage 3 AKI. However, AKI or Stage 3 AKI were not
associated with mortality [12]. Table 2 describes the incidence
of AKI and the proportion of patients requiring RRT in kidney
transplant and non-transplanted patients hospitalized due to
COVID-19 infection.
If we consider the incidence of AKI in the general population
and in kidney transplant patients, available data do not clearly
support a higher incidence of AKI in transplanted patients.
However, this statement should be taken with caution since
more information is needed, especially, in kidney transplant
patients.
AKI AND HISTOLOGY
Acute tubular necrosis is the main finding in patients with AKI
[36, 37]. However, a high proportion of patients display protein-
uria (44–66%) and microhaematuria (27–42%), suggesting that, in
addition to classical factors leading to AKI, a direct cytopathic
effect of the virus may contribute to renal damage [21, 38].
Angiotensin-converting enzyme 2 receptor is highly expressed
in kidney podocytes and tubular cells, and viral particles have
been observed in electron microscopy studies [36, 38, 39]. In the
vast majority of patients, haematuria and proteinuria rapidly
disappeared; however, in patients with severe proteinuria,
collapsing glomerulopathy [40–45], minimal change disease,
thrombotic microangiopathy [46, 47] and pauci-immune cres-
centic glomerulonephritis [48] have been described.
In kidney transplant patients there is scarce information on
histological findings. In patients with AKI, apart from acute tubu-
lar injury, minimal change disease [49], cortical necrosis [50] and















Jager et al. [7] ERA-EDTAa 1 February–30 April 1013 14 (13–16) 2.7 5.23
(4.92–5.56)
–
























Cravedi et al. [11] TANGO
Consortiumb
2 March–15 May 144 14.7
(12.2–17.2)
– 100
Fava et al. [12] Catalonia
Albacetec
4 March–17 April 112 15.8
(13.1–19.0)
– – 97.3
Bossini et al. [15] Brescia (Italy) 1 March–16 April 53 44.2
(33.9–57.3)
– – 84.9
Elias et al. [14] Parisd 1 March–30 April 66 54.3
(42.9–68.5)
– – 90.9
Crespo et al. [16] Barcelonee 12 March–4 April 16 49.4
(30.6–78.7)
– – 100
Mehta et al. [17] New York-
Bronxf
16 March–2 June 228 234
(209–262)
– – 84.1
RT with COVID-19: number of renal transplant patients diagnosed with COVID-19; Incidence RT: incidence of COVID-19 in renal transplant patients per 1000 patients
at risk provided by national registries; Incidence in GP: incidence of COVID-19 in the general population provided by the national registries. The relative risk of renal
transplants versus general population was calculated by standard formulas.
aThe ERA-EDTA registry only includes renal transplants from Spain and France in this report.
bTANGO consortium: 12 centres from the USA (n¼6), Italy (n¼4) and Spain (n¼2).
cRenal transplants managed in four hospitals from Catalonia and Albacete (Spain).
dProspective study in renal transplant patients managed at Hospital Saint Louis and Hospital Bichat from Paris (France).
eRenal transplant patients >65 years of age managed by Hospital del Mar from Barcelona (Spain).
fSymptomatic patients diagnosed by RT-PCR (n¼132) and by serology (n¼96). Hospitalization rate for the overall cohort was 48.5% (111 of 228 patients).
Table 2. Incidence of AKI and need for RRT in hospitalized kidney
transplant patients and in the general population with COVID-19
infection
No. of patients % AKI % RRT
Kidney transplantation
Marinaki et al. [33] 345 44.0 9.9
Favá et al. [12] 104 45.0 Not reported
Cravedi et al. [11] 144 52.0 Not reported
Elias et al. [14] 66 42.0 11.0
Weighted average 659 45.7 10.1
General population
Chan et al. [25] 3993 46.0 8.7
Fisher et al. [23] 3345 56.9 4.9
Richardson et al. [26] 2351 22.2 3.2
Ng et al. [24] 9657 39.9 6.6
Weighted average 19 346 41.9 6.3
Incidence of AKI in studies including >1000 patients from the general popula-
tion and studies including >50 kidney transplant patients. The incidence of AKI
and the need for RRT was summarized as the weighted average.
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collapsing glomerulopathy [51–53] have also been described. In ad-
dition, very few cases of T cell– or antibody-mediated rejection
have been described, raising the question of whether COVID-19 in-
fection may enhance the alloimmune response [46, 50].
ACUTE RESPIRATORY DISTRESS SYNDROME
(ARDS) IN RENAL TRANSPLANT PATIENTS
WITH COVID-19
In the general population, the spectrum of COVID-19 varies
widely, from asymptomatic to pneumonia and life-threatening
complications, including ARDS, multisystem organ failure and
ultimately death. ARDS occurs because of an acute systemic in-
flammatory response that can be caused by insults to the lung,
either direct or indirect. The reported incidence of ARDS in the
general population is 12–31%, being severe in 56–79% of cases
[26, 54–60]. Age and the presence of comorbidities are the main
risk factors for developing ARDS [61].
Kidney transplant recipients may be at high risk of develop-
ing severe COVID-19 disease due to chronic immunosuppres-
sion, comorbidities and frequent contact with the healthcare
system. Indeed, they may be more likely to be diagnosed when
they have symptoms due to closer follow-up at the transplant
centre [8, 62–64]. However, there are few studies comparing
ARDS in kidney transplant patients and the general population.
In a study conducted at our centre [63], 46 solid organ transplant
(SOT) recipients (30 renal transplants) admitted due to COVID-
19 were matched by age, sex and age-adjusted Charlson comor-
bidity index to 166 controls. As expected, hypertension and
chronic kidney disease were more frequent in transplant recipi-
ents. A total of 27 (58.7%) transplant recipients and 71 (42.8%)
controls suffered progressive respiratory failure. In a similar
study conducted in Michigan, 41 SOT recipients (67% were
Black; 16 single and 5 combined kidney transplants) were
matched by age, race and admission status to 121 controls [32].
Severe disease-adjusted risk of death was similar in both
groups and the severity of COVID-19 and number of intubations
were also similar, but the incidence of AKI requiring RRT was
higher in transplant patients (29.3% versus 5.8%).
Data from multicentre studies yielded similar results;
Cravedi et al. [11] identified 144 hospitalized adult kidney trans-
plant recipients and 29% required orotracheal intubation. A
Spanish multicentre kidney transplant study with 104 hospital-
ized patients reported that 54.8% developed ARDS and that
it was associated with obesity [odds ratio (OR) 2.63; P¼ 0.04] [12].
No significant age difference was found between patients who
developed or did not develop ARDS; however, the elderly may
have a higher risk of death. Bossini et al. [15] found that in 45
patients admitted to the hospital due to severe symptoms, 60%
developed ARDS. A trend for an increased risk of ARDS was
recorded in patients on tacrolimus fOR 2.77 [95% confidence in-
terval (CI) 0.91–8.9]g, whereas a protective trend towards the
risk of ARDS was a transplant vintage >10 years [OR 0.37 [95% CI
0.12–1.1]) and the presence of GI symptoms at disease onset [OR
0.21 (95% CI 0.04–1.1)]. Similarly, Akalin et al. [65] reported an ini-
tial series of 36 patients with COVID-19; 28 were admitted to the
hospital and 27 (96%) had radiographic findings that were con-
sistent with viral pneumonia. Eleven of 27 (39%) required me-
chanical ventilation and 7 of them (64%) died. Table 3 describes
the incidence of ARDS and its severity in kidney transplant
patients and in the general population hospitalized for COVID-
19 infection.
Despite the high incidence of ARDS in the transplanted
population and its deleterious consequences, more detailed
studies are neeeded to support that organ transplant recipients
receiving chronic immunosuppression are more prone to de-
velop ARDS than the general population.
During the first wave of the pandemic, the most widely used
agents with presumed antiviral activity were hydroxychloroquine,
antibiotics (azithromycin) and protease inhibitors, showing no
benefit for prevention or treatment in both the general [54, 66–68]
and SOT populations [8, 9, 11, 12, 14, 15], and increasing the risk
of interactions with other drugs [63, 69]. In the general population,
remdesivir has been shown to decrease the in-hospital stay, but
with no effect on the mortality rate. Importantly, its use is con-
traindicated in patients with an estimated glomerular filtra-
tion rate (eGFR)<30 mL/min/1.73 m2 and there are no studies
on the use of remdesivir in the transplanted population [70].
It has been shown that besides viral evasion to immune re-
sponse, cytokine storm plays an important role in COVID-19 dis-
ease progression. Thus efforts have been made to mitigate the
immune response with immunomodulators and large reviews
exist on the potential role, efficacy and safety of these agents in
the management of severe COVID-19 [71, 72]. Non-randomized
studies have shown that treatment with tocilizumab in criti-
cally ill patients may offer some benefit in both the general [73]
and kidney transplant population [74]. However, prospective
randomized studies in hospitalized patients with COVID-19
pneumonia showed that although tocilizumab may reduce the
likelihood of progression to mechanical ventilation, it did not
improve survival [75, 76]. Importantly, the large RECOVERY trial
showed that dexamethasone decreases 28-day mortality among
those who were receiving either invasive mechanical ventila-
tion or oxygen alone, but not among those receiving no respira-
tory support [77]. Thus research efforts should focus not only on
the most relevant immunomodulatory strategies, but also the
optimal timing of such immunomodulatory interventions to
maximize the therapeutic effect [71].
In kidney transplantation, the most widely used interven-
tions were the modification of immunosuppression, reducing or
suspending the antimetabolite or inhibitors of the mammalian
Table 3. Incidence of ARDS in hospitalized kidney transplant recipi-
ents and the general population with COVID-19 infection
References
No. of
patients % ARDS % Severe
Kidney transplantation
Coll et al. [8] 375 35.7 Not reported
Cravedi et al. [11] 144 29.0 Not reported
Favà et al. [12] 104 54.8 16.3
Bossini et al. [15] 45 60.0 Not reported
Elias et al. [14] 66 68.0 Not reported
Cavalcanti et al. [66] 36 39.0 Not reported
Weighted average 770 41.4 16.3
General population
Petrilli et al. [58] 1099 16.7 72.9
Richardson et al. [26] 2634 12.2 Not reported
Berengue et al. [59] 2741 23.6 60.4
Cummings et al. [60] 3979 31.5 67.4
Wu et al. [61] 1150 22.0 79.0
Weighted average 11 603 21.2 55.6
Incidence of ARDS in studies including >1000 patients from the general popula-
tion and studies including >30 kidney transplant patients. The incidence of
ARDS and its severity was summarized as the weighted average.
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target of rapamycin, while the calcineurin inhibitor was
suspended in patients at risk for interaction with protease
inhibitors [8, 11, 12, 66, 78]. Recently, the in vitro efficacy of cy-
closporine A and FK506 to inhibit the replication of SARS-CoV-1
and other human coronaviruses has been reported [79];
however, there is no clinical evidence for a protective effect to
reduce the likelihood of severe COVID-19 or to treat the cytokine
storm. Also, there is no evidence on what the management of
immunosuppression should be. An approach like that of other
serious viral infections (mycophenolate withdrawal and calci-
neurin inhibitor reduction) seems a safe option since this
change in immunosuppression has been associated with very
low incidences of acute rejection.
PATIENT MORTALITY AND RISK FACTORS FOR
DEATH IN RECIPIENTS WITH COVID-19
A British population-based study showed that SOT patients had
one of the highest in-hospital risks of death (HR 4.23) due to
COVID-19 [80]. In a large multicentre US study (423 SOT patients,
including 318 kidney or kidney–pancreas recipients), the overall
mortality rate by Day 28 was 20.5% among the hospitalized
patients and 18.5% among the overall cohort [62]. Risk factors
for mortality included age >65 years, chronic heart failure,
chronic lung disease and obesity. Also, the presence of pneumo-
nia and lymphopaenia at diagnosis were independently associ-
ated with mortality. Of interest, none of the multiple surrogates
for immunosuppression that were explored showed any associ-
ation with mortality.
Focusing on renal transplants, a recent systematic review
based on 20 studies from different countries revealed a patient
mortality higher than in general population, ranging between
18% and 43% [81]. Risk factors associated with mortality
(Table 4) included older age [13, 15, 74, 82–84], plasma viral load
[82] and the presence of higher inflammatory biomarkers such
as C-reactive protein, interleukin-6 (IL-6), D-dimer or serum lac-
tate dehydrogenase [8, 12, 74, 82]. Interestingly, in a Turkish co-
hort of 40 renal recipients, the use of previous antirejection
treatment was an independent predictor for mortality and the
use of cyclosporine as a maintenance immunosuppressant was
associated with better survival [85]. Likewise, in a study that in-
cluded 29 renal transplant patients, patients on cyclosporine-
based immunosuppression experienced less mortality com-
pared with immunosuppression minimization [86].
The Spanish registry included 423 kidney transplants with a
mortality rate of 28% [8]. Interestingly, the mortality rate de-
clined to 15.8% after adjusting for age and gender, implying that
baseline characteristics rather than the immunosuppressive
state or the transplant itself has a remarkable effect on survival.
Overall, the risk of death increased with age (>60 years) and
mortality was higher among recipients who developed ARDS
and in those with nosocomial COVID-19. No differences were
found regarding baseline immunosuppression between survi-
vors and non-survivors, but in patients with ARDS in whom the
antimetabolite agent was discontinued, the mortality was lower
[8]. A French registry–based study that included 279 renal trans-
plant patients reported a mortality rate of 22.8% and indepen-
dent risk factors for mortality included age >60 years,
cardiovascular disease and dyspnoea [9].
In the TANGO multicentre study (144 hospitalized kidney
transplants), the mortality rate was 32% and older age, lower
lymphocyte counts, higher lactate dehydrogenase, procalcito-
nin and IL-6 levels and lower eGFR were associated with mortal-
ity [11]. Moreover, the presence of dyspnoea at onset (61%
versus 83%) was associated with mortality while the presence of
diarrhoea was more frequent in survivors (45% versus 24%).
Other factors such as the type of transplantation (living versus
deceased donor), time post-transplantation (<1 versus >1 year),
comorbidities or type of immunosuppression were not associ-
ated with mortality. None of the treatment strategies with
Table 4. Risk factors independently associated with mortality in renal transplant recipients with SARS-CoV-2 infection
Variable References Reference group Relative risk 95% CI
Age Craig-Shapiro et al. [6]
Coll et al. [8]
Caillard et al. [9]
Cravedi et al. [11]
Benotmane et al. [82]
Favà et al. [12]






















Gender Craig-Shapiro et al. [6] Male 5.7 1.5–21.7






Nosocomial COVID-19 Coll et al. [8] Yes 3.0 1.9–4.9
Dyspnoea at onset Cravedi et al. [11]
Fava et al. [12]







Diarrhoea at onset Cravedi et al. [11] Yes 0.4 0.2–0.9
Acute respiratory
distress syndrome
Coll et al. [8]







Lactate dehydrogenase Cravedi et al. [11]







C-reactive protein Fava et al. [12] mg/L 1.003 1.002–1.005
Pro-calcitonin Cravedi et al. [11] >0.5 ng/mL 3.0 1.4–6.9
eGFR Cravedi et al. [11] mL/min 0.97 1.07–3.9
Cardiovascular disease Caillard et al. [9] Yes 2.04 1.07 3.9
Diabetes Craig-Shapiro et al. [6] Yes 2.97 1.03–8.57
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antivirals used to treat COVID-19 had any impact on survival.
Again, patients with nosocomial SARS-CoV-2 infection had the
highest mortality rate (77.8%) [11].
In a multicentre study from Spain that included 104 kidney
recipients, the mortality rate was 28% and older age, higher se-
rum lactate dehydrogenase and having ARDS at admission were
independently associated with a higher risk of death [12].
A Belgium registry–based study that included 46 kidney
transplant recipients with COVID-19 showed a mortality similar
to that reported in the general population (14% versus 15.3%),
but much lower than in patients on dialysis (14% versus 29%)
[10].
In another study that involved several European countries
(ERACODA), 305 renal transplant patients were included, with a
28-day mortality rate of 21.3% as compared with 25% in patients
on dialysis, and older age was the predominant risk factor for
mortality in renal recipients [87].
Most of the available data on survival involves long-term
stable recipients, and there is scarce information regarding
early transplant recipients. In studies in which the subgroup of
early transplant recipients was analysed for <6 months [12] or
<1 year [12, 88], mortality was not different between groups, al-
though in some of them there was a trend towards a higher
mortality for the early group [12]. A recent report that included
24 recipients with COVID-19 diagnosed within 60 days after
transplantation revealed a significant impact on patient sur-
vival with a mortality rate of 46% [89]. Recipients who died were
older (61 versus 70 years), received high-dose steroids less fre-
quently (25% versus 82%) and usually needed ventilation sup-
port (15% versus 78%). In another study that included 237
patients in the first-year post-transplant, of whom 16 had a
COVID-19 diagnosis, the mortality rate was 37% [90].
In this pandemic era, management of induction and mainte-
nance immunosuppression has been challenging to clinicians
treating kidney transplant patients. Regarding the use of induc-
tion therapy with lymphocyte-depleting agents (anti-thymocyte
globulins, alemtuzumab and rituximab), a large study con-
ducted in the USA showed that their use decreased during the
first several weeks of the pandemic compared with the three
previous years, while the use of basiliximab or no induction in-
creased. Importantly, during the pandemic, lymphocyte-
depleting agents were associated with a lower risk of acute re-
jection, but without significant differences in mortality. These
results question whether this shift in induction immunosup-
pression was a safe and effective approach to address the novel
infectious risk [91]. Additionally, small studies conducted in
single centres show that renal transplant patients treated with
thymoglobulin who acquired the COVID-19 infection early after
transplantation had a modest risk for severe disease [92], espe-
cially using low doses [93]. However, it seems prudent to moni-
tor absolute lymphocyte count following lymphocyte-depleting
induction and consider temporary an antimetabolite dose re-
duction in patients with severe lymphopaenia [92]. Conversely,
management of steroids was not modified in the USA during
the pandemic and the practice of steroid avoidance/withdrawal
has not been modified and its use did not modify the graft fail-
ure or mortality rates [91].
OUTCOMES IN KIDNEY RECIPIENTS VERSUS
PATIENTS ON THE WAITING LIST
Since the beginning of the pandemic, all transplant pro-
grammes have dramatically reduced their activity [94, 95]. In
the early outbreak period, general recommendations from the
different societies in areas in which the virus was widespread
implied avoiding living-donor transplantation and reserving
deceased-donor transplantation for life-threatening conditions
or for hypersensitized patients with a suitable donor [96–98]. In
this pandemic scenario, there are several studies that aimed to
address whether it would be safer to undergo a renal transplan-
tation or remain on the waiting list. In a single-centre study in
which the outcomes of 56 patients included on the waiting list
were compared with the outcomes of 80 kidney transplant
recipients, wait-listed patients with COVID-19 were not only
more likely to require more hospitalization (82% versus 65%),
but also had an increased risk of death (25% versus 16%), with
comparable baseline demographics and comorbidities between
groups [6]. In this cohort, risk factors independently associated
with mortality were wait list status, male sex, age and diabetes.
On the same note, in a registry-based study from France in
which renal transplant recipients and patients included on the
waiting list were compared in different time periods, an in-
crease in deaths was detected in both populations between
March and June 2020 as compared with the same period in the
two previous years [99]. This was explained by COVID-19, which
caused the deaths of 44% of recipients and 42% of wait-listed
patients. Interestingly, the increase in risk of death in both pop-
ulations was similar in high-risk geographic areas, but in low-
risk areas the risk of death in wait-listed patients 4-fold higher,
but there was no additional risk for renal transplant recipients,
suggesting that transplant programmes should not be sus-
pended in geographic areas with a low spread of infection. In a
multicentre study in London, an area with a high prevalence of
COVID-19 [100], outcomes after SARS-CoV-2 infection in kidney
transplant recipients (n¼ 121) were compared with patients on
the waiting list (n¼ 51). Although no differences in mortality
were found (30% versus 27%), the only risk factor independently
associated with mortality was being >60 years of age in the kid-
ney transplant group [OR 4.3 (95% CI 1.8–10.2)] [88]. Finally, in
contrast with the previous data, there is a single-centre study
performed in London in which the overall survival on a popula-
tion level between wait-listed and kidney transplant patients
was not different, but the mortality rate following SARS-CoV-2
infection was higher in the renal transplant group (37% versus
11%) [90]. Few studies exist in the paediatric population, but the
available data support that since chronic immunosuppression
is not associated with an increased risk of COVID-19 in young
kidney transplant patients, transplant activity should be main-
tained even in areas with a high incidence of SARS-CoV-2 infec-
tion [101].
CONCLUSIONS
The COVID-19 pandemic has been challenging for kidney trans-
plantation programmes around the world, with a big impact on
transplant policies and in the management of infected and
uninfected patients. The rate of infected transplants was high
in geographic areas with widespread infection and patient out-
comes were compromised due to high rates of complications
and COVID-19-related deaths. In managing infected patients
during the pandemic, only the use of steroids and remdesivir
has been demonstrated to be useful after performing random-
ized controlled clinical trials. Since chronic immunosuppression
may influence a patient’s outcome, different changes based on
art and theory were applied. Thus, in the absence of trial-based
evidence, we should include transplant patients in prospective
studies and registries to help guide optimal care [102].
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